Future clinical prospects of C-peptide testing in the early diagnosis of gestational diabetes.

Autor:	Milionis C; Department of Endocrinology, Diabetes, and Metabolism, 'Elena Venizelou' General Hospital, Athens 11521, Greece. pesscharis@hotmail.com., Ilias I; Department of Endocrinology, Diabetes, and Metabolism, 'Elena Venizelou' General Hospital, Athens 11521, Greece., Lekkou A; Department of Endocrinology, Diabetes, and Metabolism, 'Elena Venizelou' General Hospital, Athens 11521, Greece., Venaki E; Department of Endocrinology, Diabetes, and Metabolism, 'Elena Venizelou' General Hospital, Athens 11521, Greece., Koukkou E; Department of Endocrinology, Diabetes, and Metabolism, 'Elena Venizelou' General Hospital, Athens 11521, Greece.
Jazyk:	angličtina
Zdroj:	World journal of experimental medicine [World J Exp Med] 2024 Mar 20; Vol. 14 (1), pp. 89320. Date of Electronic Publication: 2024 Mar 20 (Print Publication: 2024).
DOI:	10.5493/wjem.v14.i1.89320
Abstrakt:	Gestational diabetes is typically diagnosed in the late second or third trimester of pregnancy. It is one of the most common metabolic disorders among expectant mothers, with potential serious short- and long-term complications for both maternal and offspring health. C-peptide is secreted from pancreatic beta-cells into circulation in equimolar amounts with insulin. It is a useful biomarker to estimate the beta-cell function because it undergoes negligible hepatic clearance and consequently it has a longer half-life compared to insulin. Pregnancy induces increased insulin resistance due to physiological changes in hormonal and metabolic homeostasis. Inadequate compensation by islet beta-cells results in hyperglycemia. The standard oral glucose tolerance test at 24-28 wk of gestation sets the diagnosis. Accumulated evidence from prospective studies indicates a link between early pregnancy C-peptide levels and the risk of subsequent gestational diabetes. Elevated C-peptide levels and surrogate glycemic indices at the beginning of pregnancy could prompt appropriate strategies for secondary prevention. Competing Interests: Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article. (©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu